PMID- 31466817
OWN - NLM
STAT- MEDLINE
DCOM- 20200227
LR  - 20200227
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 215
IP  - 10
DP  - 2019 Oct
TI  - Over expression of amphiregulin promoted malignant progression in gastric cancer.
PG  - 152576
LID - S0344-0338(19)30781-2 [pii]
LID - 10.1016/j.prp.2019.152576 [doi]
AB  - Human Amphiregulin (AREG) was found to be over expressed in many types of cancer 
      patients including gastric cancer (GC). However, its role in GC development 
      remained unknown. In this study, over expression of AREG in MGC803 and SGC7901 GC 
      cells were conducted by gene transfection through utilizing gateway recombinant 
      cloning technology. Meanwhile, AREG knocked down in BGC823 and MKN45 GC cells 
      were achieved by lentvirus-mediated shRNA oligos infection. The results showed 
      that over expression of AREG promoted cancer cells proliferation, invasion and 
      migration, prevented apoptotic cell death and facilitated cell cycle progression. 
      However, the above AREG-mediated oncogenic phenotypes were reversed while AREG 
      was knocked down in cancer cells. Furthermore, the expression of AREG in GC cells 
      was associated with higher level of activation of both ERK/JNK/p38 and PI3K/Akt 
      signaling pathways, which were also diminished by AREG knocked down. Finally, the 
      result from study in vivo showed that the silencing AREG expression by AREG 
      knocked down inhibited tumor growth in nude mice. Collectively, the data provided 
      a convincingly laboratory evidence that over expression of AREG promoted 
      malignant procession via activation of ERK/JNK/p38 and PI3K/Akt signaling 
      pathways. Thus AREG possessed an oncogenic activity and could be served as a 
      target for gastric cancer therapy.
CI  - Copyright (c) 2019 The AoYang Cancer Research Institute of Jiangsu University. 
      Published by Elsevier GmbH.. All rights reserved.
FAU - Jiang, Jiajia
AU  - Jiang J
AD  - The AoYang Cancer Research Institute of Jiangsu University, 279 Jingang Blvd., 
      Zhangjiagang, Suzhou, 215600, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Pathology, Nanjing Medical University, Nanjing, 210029, China; Key 
      Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029. China; Jiangsu Collaborative Innovation Center For 
      Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210029. China.
FAU - Tang, Qi
AU  - Tang Q
AD  - Department of Pathology, Nanjing Medical University, Nanjing, 210029, China; Key 
      Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029. China; Jiangsu Collaborative Innovation Center For 
      Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210029. China.
FAU - Wang, Bing
AU  - Wang B
AD  - Department of Oncology, Affiliated AoYang Hospital of Jiangsu University, 279 
      Jingang Blvd., Zhangjiagang, Suzhou, 215600, China.
FAU - Li, Xiaohua
AU  - Li X
AD  - The AoYang Cancer Research Institute of Jiangsu University, 279 Jingang Blvd., 
      Zhangjiagang, Suzhou, 215600, China; National Center of Gene Testing Technology 
      Application & Demonstration, Anhui, 230088, China; The Laboratory of Clinical 
      Genomics, KingMed Diagnostics Group, Hefei, 230088, China. Electronic address: 
      joshua28li@163.com.
FAU - Feng, Zhenqing
AU  - Feng Z
AD  - The AoYang Cancer Research Institute of Jiangsu University, 279 Jingang Blvd., 
      Zhangjiagang, Suzhou, 215600, China; Department of Pathology, Nanjing Medical 
      University, Nanjing, 210029, China; Key Laboratory of Antibody Technique of 
      Ministry of Health, Nanjing Medical University, Nanjing, 210029. China; Jiangsu 
      Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical 
      University, Nanjing, 210029. China. Electronic address: fengzhenqing@njmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20190810
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Amphiregulin)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Amphiregulin/genetics/*metabolism
MH  - Apoptosis/physiology
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Cell Proliferation/physiology
MH  - Disease Progression
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/*physiology
MH  - Stomach Neoplasms/genetics/*metabolism/pathology
OTO - NOTNLM
OT  - Amphiregulin
OT  - Cell signaling
OT  - Gastric cancer
OT  - Oncogenic progression
EDAT- 2019/08/31 06:00
MHDA- 2020/02/28 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/04/25 00:00 [received]
PHST- 2019/07/17 00:00 [revised]
PHST- 2019/07/31 00:00 [accepted]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2020/02/28 06:00 [medline]
PHST- 2019/08/31 06:00 [entrez]
AID - S0344-0338(19)30781-2 [pii]
AID - 10.1016/j.prp.2019.152576 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2019 Oct;215(10):152576. doi: 10.1016/j.prp.2019.152576. Epub 
      2019 Aug 10.